Barramundi’s portfolio outperformed its benchmark in October, but two holdings each fell 46% after company-specific setbacks. The NZX-listed investment company also added Wesfarmers as its one new position during the month.
- 2.0% gross portfolio return versus 1.7% benchmark in October
- NextDC and Maas Group each fell 46%
- Share price remained 16.8% below $0.54 NAV
- Wesfarmers added to the 25-35 stock portfolio
- One-year adjusted NAV return was -14.0%
October gains masked two 46% portfolio setbacks
Barramundi Limited (NZX:BRM) delivered a 2.0% gross portfolio return in October, narrowly beating the 1.7% return from its S&P/ASX 200 benchmark hedged 70% into New Zealand dollars. Its adjusted NAV rose 1.8%, while total shareholder return was 2.3%.
That apparently steady month concealed severe damage in two holdings. Maas Group and NextDC each fell 46% in Australian dollar terms, making them the portfolio’s largest negative contributors. Maas was hit after Firmus withdrew its proposed initial public offering, leaving the AI data-centre developer working on a funding solution for its continued rollout. Barramundi said Maas responded by buying back its own shares.
NextDC’s fall followed a cut to FY27 earnings guidance after power-supply work for its M3 Melbourne data centre was suspended amid community opposition. The delay has pushed additional grid capacity into FY28, postponing the point at which NextDC can deliver capacity to customers and begin billing them. The company said the contracts had been delayed rather than lost, while demand for its existing and planned facilities remained strong.
Software, healthcare and aerospace holdings led gains
Wisetech rose 26%, helped in part by ASIC concluding its investigation into share trading by the company’s founder without taking action. Xero gained 9% after appointing former Micron Technology chief executive Mark Durcan to its board. PWR advanced 13% after upgrading its FY27 Aerospace division growth guidance from 30% to 50%, following an order for early-stage work on a potentially sizeable programme.
ResMed climbed 11% after reporting a 12% increase in underlying first-quarter FY27 profit and 6% constant-currency revenue growth. Gross margin also improved, although the manager noted that some US supply-chain expansion costs had shifted into the second quarter and that recent price increases had yet to provide much benefit. HUB24 gained 15% after a stronger-than-expected September-quarter update, with continued adviser adoption and market-share gains, particularly in superannuation.
The result extended the recovery described in Barramundi’s September-quarter rebound, but the longer record remains difficult. Adjusted NAV was down 14.0% over one year, while gross portfolio performance fell 12.5% and total shareholder return dropped 30.0%. The figures are non-GAAP measures and are not directly interchangeable: the shareholder return incorporates the share price, dividends and other specified shareholder outcomes, while gross performance is before expenses, fees and tax.
Discount persists as Wesfarmers enters the portfolio
Barramundi’s shares stood at $0.45 against a $0.54 NAV at 31 October, a 16.8% discount. The portfolio held 25 to 35 stocks, with financials representing 33%, materials 13%, information technology 13% and healthcare 12%. Its five largest positions were BHP Group at 8%, Commonwealth Bank at 7%, Macquarie Group at 6%, ANZ Group at 5% and ResMed at 5%.
The manager added Wesfarmers, citing the scale and value positions of Bunnings and Kmart and the group’s record of capital allocation. The move adds another diversified consumer exposure, but it also leaves the portfolio’s near-term performance tied to whether the manager’s recovery in software, data-centre and other growth holdings can withstand the setbacks already visible in October.
Bottom Line?
October’s benchmark-beating return was encouraging, but the persistent NAV discount and sharp single-stock losses leave the recovery vulnerable to further company-specific shocks.
Questions in the middle?
- Can NextDC secure a workable solution for M3 Melbourne’s power constraints before the delayed capacity affects more forecasts?
- Will Firmus obtain funding, and how much of Maas Group’s contracted AI data-centre work ultimately proceeds?
- Can Barramundi narrow its 16.8% discount to NAV while rebuilding performance after a difficult one-year period?